Intellia Therapeutics

Intellia Therapeutics is a clinical-stage genome editing company focused on utilizing CRISPR/Cas9 systems to engineer curative in vivo and ex vivo treatments. The company pioneered systemic in vivo CRISPR editing in humans through candidates like NTLA-2001 for transthyretin amyloidosis and NTLA-2002 for hereditary angioedema. Through targeted lipid nanoparticle delivery and modular guide RNA engineering, Intellia Therapeutics works to permanently knock out disease-causing genes directly inside the body.